Trump Orders Cannabis Rescheduling To Schedule III In Major Federal Shift

President Donald Trump announced today that he will sign an executive order directing the federal government to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, marking the most significant federal shift in U.S. cannabis policy in more than five decades.

“Today, I’m pleased to announce that I will be signing an executive order to reschedule marijuana from a Schedule I to a Schedule III controlled substance with legitimate medical uses,” Trump said during a White House event flanked by senior federal health officials, physicians and veterans’ representatives.

The president framed the decision as a medical and research-driven correction rather than a step toward legalization, repeatedly stressing that the move does not change cannabis’s legal status for recreational use.

“The order I am about to sign is not the legalization of marijuana in any way, shape, or form, and in no way sanctions its use as a recreational drug,” Trump said. “It has nothing to do with it.”

What Schedule III means, in plain terms

Moving cannabis to Schedule III would formally recognize that marijuana has accepted medical use under federal law while remaining a controlled substance subject to regulation and oversight.

Trump said the change reflects longstanding patient demand and medical consensus. “For decades, this action has been requested by American patients suffering from extreme pain, incurable diseases, aggressive cancers, seizure disorders, neurological problems and more, including numerous veterans,” he said.

Schedule III status is widely expected to ease barriers to federally sanctioned research. Trump emphasized that point directly: “This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments.”

The business impact everyone will watch first: 280E

For operators and investors, the most immediate financial implication is the potential end of IRS Code Section 280E, which bars businesses trafficking Schedule I or II substances from taking standard tax deductions.

If cannabis is ultimately treated as a Schedule III substance for tax purposes, many plant-touching operators could see materially lower effective tax rates. Markets have been pricing in that possibility for months, though implementation details will determine how quickly and uniformly relief applies.

What rescheduling does not do

Trump went out of his way to narrow expectations.

“This is not legalization,” he said, adding that recreational drug use remains unsafe and that cannabis should only be used when “recommended by a doctor for medical reasons.”

Rescheduling does not resolve several core industry constraints:

• No federal legalization: Cannabis remains illegal under federal law and the federal–state conflict persists.
• No automatic banking or interstate commerce solution: Congressional action would still be required to address financial services access and cross-border trade.
• No immediate clarity on workplace drug testing: Safety-sensitive and DOT-regulated employment rules are unlikely to change absent targeted regulatory updates.

Opioids, veterans and medical framing

A central theme of Trump’s remarks was cannabis as a potential alternative to opioids.

“In some cases, this may include use as a substitute for addictive and potentially lethal opioid painkillers,” he said, arguing that cannabis can reduce suffering without the same risk profile.

He also highlighted veterans and end-of-life care, saying cannabis may allow patients to maintain clarity and “die with dignity,” a line that drew particular attention given the presence of the American Legion at the event.

A signal on CBD and hemp

Trump also previewed a potential next policy debate, saying the administration is asking Congress to reconsider how hemp-derived CBD is classified.

“We’re also asking Congress to reconsider its classification of hemp-derived CBD to ensure seniors can access CBD products they have found beneficial for pain and other reasons,” he said.

That statement could have implications for the rapidly evolving hemp and cannabinoid market, especially amid growing scrutiny of intoxicating hemp products.

Why the “how” matters: implementation and rulemaking

Despite the announcement, the real-world impact hinges on execution.

Even with a signed executive order, outcomes will depend on:

• How DEA, DOJ and HHS interpret and implement the change
• Whether FDA expands or tightens oversight of cannabis-derived products
• How quickly agencies issue guidance affecting taxes, research and compliance

Trump underscored that the move is rooted in what he called “common sense,” but left operational details to federal agencies and future rulemaking.

What happens next

Operators, investors and policymakers will be watching closely for:

• Mechanism and timeline: Including effective dates and transition milestones
• Agency guidance: Particularly from DEA, DOJ, HHS and FDA
• Legal and compliance fallout: Including potential challenges or new regulatory burdens that could reshape competitive dynamics

IgniteIt will continue updating this story as the White House releases primary documentation and federal agencies clarify how rescheduling will be implemented in practice.